# Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/niraparib-monotherapy-for-late-line-treatment-of-ovarian-cancer-quadra-a/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kathleen N. Moore,Angeles Alvarez Secord,Melissa A. Geller,David S. Miller,Noelle Cloven,Gini F. Fleming,Andrea E. Wahner Hendrickson,Masoud Azodi,Paul DiSilvestro,Amit M. Oza,Mihaela Cristea,Jonathan S. Berek,John K. Chan,B.J. Rimel,Daniela Matei,Yong Li,Kaiming Sun,Katarina Luptakova,Ursula A. Matulonis,Bradley J. Monk |
| Citations | 540 |
| DOI | 10.1016/s1470-2045(19)30029-4 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2935541805 |
| PMID | 30948273 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Paul DiSilvestro](https://scholariq.org/researchers/paul-disilvestro/)
- [Yong Li](https://scholariq.org/researchers/yong-li/)
- [Amit M. Oza](https://scholariq.org/researchers/amit-m-oza/)
- [Bradley J. Monk](https://scholariq.org/researchers/bradley-j-monk/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Paper topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.